<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593072</url>
  </required_header>
  <id_info>
    <org_study_id>7537-us-101</org_study_id>
    <secondary_id>W9113M-10-C-0056</secondary_id>
    <nct_id>NCT01593072</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of healthy male and&#xD;
      female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in&#xD;
      and to evaluate the pharmacokinetics (PK).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of 14 once daily&#xD;
      intravenous (IV) infusions of ascending doses of AVI 7537 compared to matched placebo in&#xD;
      healthy male and female subjects.&#xD;
&#xD;
      To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and&#xD;
      female subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Terminated for convenience of the Government due to funding constraits&#xD;
  </why_stopped>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The outcome measures are Serial PK Day 1 over 24 hrs(pre-dose,10 min post,30 min post, 1hr 1.5,2,4,6, 8, 12,16,24,28,32,36, and 48 hrs post-dose), daily through level and on Day 14 (last day of dosing) serial PK until 48 hrs post last dose.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The outcome measures are Serial PK Day 1 over 24 hours (pre-dose, 10 minutes post-dose , 30 minutes, 1 hour, 1.5, 2, 4, 6,. 8, 12,16,24 hours post-dose), daily trough level and on Day 14 (last day of dosing). PK Day 14 over 48 hours (post-dose, 10 minutes, 1.5, 2, 4, 6, 8, 12, 16, 24, 28, 32, 36, and 48 hours post-dose (collection of plasma pre-dose on Day 14 will also serve as the trough sample for that day).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics (PK) of 14 once daily doses of AVI-7537 in healthy male and female subjects,</measure>
    <time_frame>2 weeks</time_frame>
    <description>Efficacy will not be assessed in a Phase I study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ebola Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>AVI-7537</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AVI-7537</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal Saline Solution (NSS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVI-7537</intervention_name>
    <description>Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV&#xD;
The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.</description>
    <arm_group_label>AVI-7537</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline Solution (NSS)</intervention_name>
    <description>Normal Saline Solution (NSS)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject must meet all of the following criteria to be eligible for this study.&#xD;
&#xD;
          1. Man or woman 18 to 50 years of age, inclusive, at the time of screening.&#xD;
&#xD;
          2. Body mass index 18 kg/m2 to 35 kg/m2, inclusive, at the time of screening and Check-in&#xD;
             (Day -1).&#xD;
&#xD;
          3. Good general health (no chronic health conditions) as determined by the Investigator.&#xD;
&#xD;
          4. Female subjects must be of non-childbearing potential (e.g., be confirmed&#xD;
             post-menopausal or have undergone surgical sterilization) or must, in conjunction with&#xD;
             their sexual partner(s), use 2 forms of medically acceptable contraception (e.g., oral&#xD;
             contraception in conjunction with a male condom) during the screening period and for&#xD;
             the entire duration of the study including the 28-day post last dose follow-up.&#xD;
&#xD;
          5. Male subjects must either be sterile or agree to use, for the entire duration of the&#xD;
             study including the 28 day post last dose follow-up, a male condom and the female&#xD;
             sexual partner must also use a medically acceptable form of birth control (e.g. oral&#xD;
             contraceptives).&#xD;
&#xD;
          6. Male subjects must agree to not donate sperm for at least 30 days after the last&#xD;
             infusion of study medication.&#xD;
&#xD;
          7. Able to understand the requirements of the study, to provide written informed consent&#xD;
             (as evidenced by signature on an informed consent document that is approved by an&#xD;
             Institutional Review Board [IRB]), and agreeable to abiding by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject who meets any of the following criteria will be excluded from this study.&#xD;
&#xD;
          1. Pregnancy or breastfeeding.&#xD;
&#xD;
          2. A positive urine or blood screen for drugs of abuse, including alcohol.&#xD;
&#xD;
          3. Use of any tobacco- or nicotine-containing products (including but not limited to&#xD;
             cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or&#xD;
             nicotine gum) within 6 months prior to Check-in (Day -1).&#xD;
&#xD;
          4. A positive cotinine test indicating recent nicotine use.&#xD;
&#xD;
          5. Donated blood within 90 days or plasma within 30 days of first dose on Day 1.&#xD;
&#xD;
          6. Active substance abuse or any medical or psychiatric condition that could jeopardize&#xD;
             the subject's safety or the subject's ability to comply with the protocol.&#xD;
&#xD;
          7. Use of any medications apart from vitamins, acetaminophen, or hormonal contraception&#xD;
             within 14 days of first dose on Day 1. Subjects with mild seasonal allergies may use&#xD;
             antihistamines at the discretion of the Investigator after approval by the Sponsor&#xD;
             Medical Monitor.&#xD;
&#xD;
          8. Participation in any interventional clinical trial within 45 days of first dose on Day&#xD;
             1 (i.e., received any other investigational drug).&#xD;
&#xD;
          9. Recipient of an organ transplant (solid or hematopoietic).&#xD;
&#xD;
         10. Prolonged QTcF interval &gt; 440 ms for males or &gt; 460 ms for females using the average&#xD;
             of the triplicate electrocardiograms (ECGs) collected during screening, on Day -1, or&#xD;
             just prior to dosing on Day 1.&#xD;
&#xD;
         11. Other clinically significant ECG abnormality, as determined by the Investigator.&#xD;
&#xD;
         12. Any clinically significant abnormal hematology, chemistry, coagulation, or urinalysis&#xD;
             value, as determined by the Investigator.&#xD;
&#xD;
         13. Glomerular filtration rate (GFR) of &lt; 80 mL/min, based on the Modification of Diet in&#xD;
             Renal Disease equation.&#xD;
&#xD;
         14. Urine-albumin-to-creatinine ratio (UACR) &gt; 30 mg/g.&#xD;
&#xD;
         15. Positive test for human immunodeficiency virus (HIV-1 serology) or known HIV&#xD;
             infection.&#xD;
&#xD;
         16. Positive result for hepatitis B surface antigen (HBsAg) or for hepatitis C virus (HCV)&#xD;
             antibody.&#xD;
&#xD;
         17. Use of alcohol-containing foods or beverages within 72 hours prior to Check-in on Day&#xD;
             -1.&#xD;
&#xD;
         18. Use of caffeine-containing foods or beverages within 24 hours prior to Check-in on Day&#xD;
             -1.&#xD;
&#xD;
         19. Febrile illness or significant infection within 48 hours before administration of the&#xD;
             first dose of study drug on Day 1.&#xD;
&#xD;
        Note: Inclusion of each subject will be reviewed with a member of AVI BioPharma Clinical&#xD;
        Personnel prior to enrollment in the trial. Written approval from a member of AVI BioPharma&#xD;
        Clinical Personnel is required prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Heald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Phase I Services</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Ascending Dose (MAD)</keyword>
  <keyword>Ebola Virus</keyword>
  <keyword>Post Exposure Prophylaxis</keyword>
  <keyword>EHF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

